Bortezomib consolidation following autologous transplant in younger and older patients with newly diagnosed multiple myeloma in two phase III trials

Autor:	Hans-Heinrich Wolf, Bernd Metzner, Wolf Rösler, Jürgen Müller, Wolfram Jung, Florian Bassermann, Martin Gramatzki, Christian Langer, Hannes Wandt, Monika Engelhardt, Peter Liebisch, Hans Salwender, Hermann Einsele, Martin Kropff, Thomas Fischer, Martin Vogel, Herbert G. Sayer, Christian Straka, Wolfram Brugger, Heinz Dürk, Stefan Knop
Rok vydání:	2019
Předmět:	Oncology Adult Male medicine.medical_specialty Phase iii trials Adolescent Antineoplastic Agents Newly diagnosed Transplantation Autologous Bortezomib 03 medical and health sciences Young Adult 0302 clinical medicine Autologous stem-cell transplantation Older patients Internal medicine Post-hoc analysis medicine Humans Multiple myeloma Aged Neoplasm Staging Aged 80 and over Consolidation (soil) business.industry Hematopoietic Stem Cell Transplantation Hematology General Medicine Middle Aged medicine.disease Prognosis Combined Modality Therapy Survival Analysis 3. Good health Consolidation Chemotherapy Treatment Outcome 030220 oncology & carcinogenesis Female business Multiple Myeloma 030215 immunology medicine.drug
Zdroj:	European journal of haematologyREFERENCES. 103(3)
ISSN:	1600-0609
Popis:	Objective A post hoc analysis of two phase III trials was carried out to explore the influence of age and treatment factors on the effect of bortezomib consolidation on progression-free survival (PFS) post autologous stem cell transplantation (ASCT). Methods Patients with newly diagnosed multiple myeloma were assigned to one of two trials (ClinicalTrials.gov IDs: NCT00416273, NCT00416208), which were conducted in parallel, based on age (18-60 or 61-75 years, respectively). Following induction and ASCT, patients were randomized 1:1 to four 35-day cycles of bortezomib consolidation (1.6 mg/m2 IV on days 1, 8, 15, 22) or observation only. Results Median PFS with bortezomib consolidation vs observation was 33.6 vs 29.0 months (P = 0.3599) in patients aged 18-60 years (n = 202), and 33.4 vs 26.4 months (P = 0.0073) in patients aged 61-75 years (n = 155), respectively. Bortezomib consolidation post-ASCT appeared to equalize outcomes between older and younger patients who received prior treatment of differing intensity. This suggests that the effect of consolidation may be relative and may depend on the composition and intensity of induction and high-dose therapy. Conclusion Older patients receiving less intensive prior treatment could experience a larger PFS benefit from bortezomib consolidation.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::78f3ba2750a9a4e00e1b4234a096b11a https://pubmed.ncbi.nlm.nih.gov/31231828 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.